Acute Lymphocytic Leukemia (ALL) – Cell Therapies 15-Market Assessment and Sales Forecast to 2031

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Acute Lymphocytic Leukemia (ALL) – Cell Therapies 15-Market Report Overview

The total market value for the 15M, which includes both cell therapies and established/traditional ALL therapies was $2.3 billion in 2021. The need for “off-the-shelf” products with lower costs and reduced infrastructure requirements raises the development of allogeneic agents thereby driving the market growth.

Acute Lymphocytic Leukemia (ALL) – Cell Therapies 15-Market Outlook, 2021-2031 ($ Billion)

Acute Lymphocytic Leukemia (ALL) – Cell Therapies 15-Market Outlook, 2021-2031 ($ Billion)

Buy the Full Report to Know More about the Acute Lymphocytic Leukemia (ALL) – Cell Therapies 15-Market Forecast

Download A Free Report Sample

The ALL–cell therapies 15-market research report offers a comprehensive insight into the market through 2032. The report provides an overview of the disease including epidemiology, symptoms, diagnosis, disease management, countries where the disease is prevalent, and leading players associated with the market.

Market Size (2021) $2.3 billion
Forecast Period 2021-2031
Key Regions ·       APAC

·       Europe

·       Middle East

·       North America

Leading Players ·       Juventas Cell Therapy

·       Autolus Therapeutics

·       Gamida Cell

·       Gilead

·       Cellectis S.A.

Enquire & Decide Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase.

Acute Lymphocytic Leukemia (ALL) – Cell Therapies 15-Market Dynamics

The first-line setting is well-served by chemotherapy with high use of stem cell transplants on relapse. This blocks the entry of cell therapies into the more lucrative settings, which is hampering the market growth. However, the inability to find a donor for stem cell transplants drives the need for stem cell replacement products such as NiCord and TRGFT-201, which will positively impact the ALL cell therapies 15-market growth in the coming years.

Acute Lymphocytic Leukemia (ALL) – Cell Therapies 15-Market Analysis by Treatment

  • The ABL1, RLF2, and JAK2 genes, among others, are implicated in several different translocations or other mutations. These are classified generally as Philadelphia chromosome (Ph)-like cytogenetics, which may respond to treatment with TKIs.
  • Novartis’s Kymriah and Gilead’s Tecartus are the only marketed cell therapy products approved for the treatment of ALL as of 2022.

Buy Full Report for More Insights into the Acute Lymphocytic Leukemia (ALL) – Cell Therapies 15-Market Treatment

Download a Free Report Sample

Acute Lymphocytic Leukemia (ALL) – Cell Therapies 15-Market Segmentation by Regions

North America had the highest sales in 15MM in the ALL-cell therapies 15-market.

A few of the key regions in the market are APAC, Europe, Middle East, and North America.

Acute Lymphocytic Leukemia (ALL) – Cell Therapies 15-Market Analysis by Regions, 2021 (%)

Acute Lymphocytic Leukemia (ALL) – Cell Therapies 15-Market Analysis by Regions, 2021 (%)

Buy the Full Report for More Regional Insights into the Acute Lymphocytic Leukemia (ALL) – Cell Therapies 15-Market

Download A Free Report Sample

Acute Lymphocytic Leukemia (ALL) – Cell Therapies 15-Market -Competitive Landscape

Hebei Senlang Biotechnology and Chongqing Precision Biotech are the leading sponsors of cell therapy trials in ALL.

A few of the major players in the Acute Lymphocytic Leukemia (ALL) – -cell therapies 15-market are:

  • Juventas Cell Therapy
  • Autolus Therapeutics
  • Gamida Cell
  • Gilead
  • Cellectis S.A.

Acute Lymphocytic Leukemia (ALL) – Cell Therapies 15-Market Analysis by Companies

Acute Lymphocytic Leukemia (ALL) – Cell Therapies 15-Market Analysis by Companies

Buy the Full Report to Know More about Companies in the Acute Lymphocytic Leukemia (ALL) – Cell Therapies 15-Market

Download A Free Report Sample

Acute Lymphocytic Leukemia (ALL) – Cell Therapies 15-Country Outlook (Value, $ Billion, 2021-2031)

  • APAC
  • Europe
  • Middle East
  • North America

Reasons to Buy

  • Assess the disease epidemiology and 10-year patient-based forecast (PBF) across the eight major pharmaceutical markets (8MM) (US, France, Germany, Italy, Spain, UK, Japan, and China) and identify the potential countries for growth opportunities within the ALL-cell therapy market.
  • Analyze the clinical and commercial landscapes of each indication, with pricing assumptions
  • Evaluate indication-specific unmet needs and competitive assessments by Class of Therapy
  • Identify the Likelihood of Approval Analysis for the most promising agents and Phase Transition Success Rate Analysis.
  • Identify key future players based on their Pipeline Strength.


  • Novartis

  • Gilead

  • Autolus Therapeutics

  • Gamida Cell

  • Orca Biosystems

  • Coimmune

  • Cellectis

  • Juventas Cell Therapy


Table of Contents

Table of Contents (PowerPoint Deck)

1. Preface

1.1. Contents

1.2. Report Scope

2. Executive Summary

3. Disease Overview

3.1. Etiology & Epidemiology

3.2. ALL Treatment Algorithm

4. Pipeline Drugs Overview

4.1. Pipeline Analysis

4.2. Target Analysis and Clinical Benchmarks

5. Market Outlook

5.1. 10-Year Market Analysis with Drivers and Barriers

6. Unmet Needs

7. Likelihood of Approval Analysis and Phase Transition Success Rate Analysis

8. Competitive Assessment

8.1. Competitive Analysis by Class of Therapy

9. Future Players

9.1. Future Players Based on Pipeline Strength

10. Appendix

10.1. Cell Therapies Forecast Methodology Overview

10.2. Pricing of Cell Therapies

10.3. Pipeline Launch Assumptions

10.4. Abbreviations

10.5. Methodology

10.6. About the Authors

11. Contact Us

Frequently asked questions

Acute Lymphocytic Leukemia (ALL) – Cell Therapies 15-Market Assessment and Sales Forecast to 2031 standard reports
Currency USD
$9,995

Can be used by individual purchaser only

$29,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Acute Lymphocytic Leukemia (ALL) – Cell Therapies 15-Market Assessment and Sales Forecast to 2031 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Acute Lymphocytic Leukemia (ALL) – Cell Therapies 15-Market Assessment and Sales Forecast to 2031 in real time.

  • Access a live Acute Lymphocytic Leukemia (ALL) – Cell Therapies 15-Market Assessment and Sales Forecast to 2031 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.